Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer

Cancer Statistics, 2021

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522 · see citing works

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · see citing works

Regulation of cancer cell metabolism

Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · see citing works

Reactive oxygen species, cellular redox systems, and apoptosis

Circu, M. L., & Aw, T. Y. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.12.022 · Cited by 3,340 · see citing works

Breast cancer statistics, 2019

Desantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Sauer, A. G., Jemal, A., & Siegel, R. L. (2019) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21583 · Cited by 3,126 · see citing works

Mitochondria as multifaceted regulators of cell death

Bock, F. J., & Tait, S. W. G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0173-8 · Cited by 2,482 · see citing works

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683 · see citing works

Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis

Sinha, K., Das, J., Pal, P. B., & Sil, P. C. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1034-4 · Cited by 1,622 · see citing works

Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis

Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,538 · see citing works

Genome-wide analysis of estrogen receptor binding sites

Carroll, J. S., Meyer, C. A., Song, J. S., Li, W., Geistlinger, T., Eeckhoute, J., Brodsky, A. S., Keeton, E. K., Fertuck, K. C., Hall, G., et al. (2006) · Nature Genetics · doi:10.1038/ng1901 · Cited by 1,368 · see citing works

Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Hay, N. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.77 · Cited by 1,124 · see citing works

Is Akt the “Warburg kinase”?—Akt-energy metabolism interactions and oncogenesis

Robey, R. B., & Hay, N. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.010 · Cited by 535 · see citing works

Endocrine Disrupting Chemicals Targeting Estrogen Receptor Signaling: Identification and Mechanisms of Action

Shanle, E. K., & Xu, W. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100231n · Cited by 521 · see citing works

Selenium compounds as therapeutic agents in cancer

Fernandes, A. P., & Gandin, V. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.10.008 · Cited by 460 · see citing works

Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

Patel, H., & Bihani, T. (2017) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 423 · see citing works

Oxidative phosphorylation: regulation and role in cellular and tissue metabolism

Wilson, D. F. (2017) · The Journal of Physiology · doi:10.1113/jp273839 · Cited by 377 · see citing works

Reactive Oxygen Species in Cancer: A Dance with the Devil

Schumacker, P. T. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.01.007 · Cited by 368 · see citing works

Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling

Luo, M., Li, S., Brooks, M. D., Jiagge, E. M., Zhu, Y., Buschhaus, J. M., Conley, S. J., Fath, M. A., Davis, A., Gheordunescu, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.006 · Cited by 354 · see citing works

Incorporating Selenium into Heterocycles and Natural Products─From Chemical Properties to Pharmacological Activities

Hou, W., & Xu, H. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01859 · Cited by 352 · see citing works

Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment

Gandin, V., Khalkar, P., Braude, J. P., & Fernandes, A. P. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.05.001 · Cited by 345 · see citing works

Selenoproteins: Antioxidant selenoenzymes and beyond

Steinbrenner, H., Speckmann, B., & Klotz, L. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.06.024 · Cited by 327 · see citing works

Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP.

Arora, K. K., & Pedersen, P. L. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77853-3 · Cited by 323 · see citing works

ROS-modulated therapeutic approaches in cancer treatment

Raza, M. H., Siraj, S., Arshad, A., Waheed, U., Aldakheel, F. M., Alduraywish, S. A., & Arshad, M. M. U. D. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2464-9 · Cited by 301 · see citing works

Treatment of Estrogen Receptor-Positive Breast Cancer

Lumachi, F., Brunello, A., Maruzzo, M., Basso, U., & Basso, S. M. M. (2013) · Current Medicinal Chemistry · doi:10.2174/092986713804999303 · Cited by 291 · see citing works

Hexokinase-I Protection against Apoptotic Cell Death Is Mediated via Interaction with the Voltage-dependent Anion Channel-1

Abu-Hamad, S., Zaid, H., Israelson, A., Nahon, E., & Shoshan-Barmatz, V. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708216200 · Cited by 278 · see citing works

Biological activity of selenium: Revisited

Wrobel, J. K., Power, R. F., & Toborek, M. J. (2015) · IUBMB Life · doi:10.1002/iub.1466 · Cited by 260 · see citing works

Emerging roles of aerobic glycolysis in breast cancer

Wu, Z., Wu, J., Zhao, Q., Fu, S., & Jin, J. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02187-8 · Cited by 260 · see citing works

Small molecule selenium-containing compounds: Recent development and therapeutic applications

Chuai, H., Zhang, S., Bai, H., Li, J., Wang, Y., Sun, J., Wen, E., Zhang, J., & Xin, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113621 · Cited by 253 · see citing works

Mitochondria as the target of the pro-apoptotic protein Bax

Er, E., Oliver, L., Cartron, P., Juin, P. P., Manon, S., & Vallette, F. M. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.05.032 · Cited by 252 · see citing works

Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse

Lee, H.-R., Kim, T., & Choi, K. (2012) · Laboratory Animal Research · doi:10.5625/lar.2012.28.2.71 · Cited by 232 · see citing works

Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer

Varghese, E., Samuel, S. M., Líšková, A., Samec, M., Kubatka, P., & Büsselberg, D. (2020) · Cancers · doi:10.3390/cancers12082252 · Cited by 208 · see citing works

Tamoxifen Resistance in Breast Cancer

Chang, M.-S. (2012) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.20.3.256 · Cited by 205 · see citing works

Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer

Montero, A. J., & Jassem, J. (2011) · Drugs · doi:10.2165/11592590-000000000-00000 · Cited by 194 · see citing works

Design, Synthesis, and Biological Evaluation of Novel Selenium (Se-NSAID) Molecules as Anticancer Agents

Plano, D., Karelia, D. N., Pandey, M. K., Spallholz, J. E., Amin, S., & Sharma, A. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01503 · Cited by 189 · see citing works

Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells

Kim, S. K., Yang, J. W., Kim, M. R., Roh, S. H., Kim, H. G., Lee, K. Y., Jeong, H. G., & Kang, K. W. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.05.011 · Cited by 171 · see citing works

Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer

Yao, J., Deng, K., Huang, J., Zeng, R., & Zuo, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.592912 · Cited by 168 · see citing works

Design, Synthesis, and Biological Evaluation of Novel Selenium-Containing Iso combretastatins and Phenstatins as Antitumor Agents

Pang, Y., An, B., Lou, L., Zhang, J., Yan, J., Huang, L., Li, X., & Yin, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00480 · Cited by 165 · see citing works

Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 axis of breast cancer cells: Combined administration of Polydatin and 2‐Deoxy‐d‐glucose

Zhang, T., Zhu, X., Wu, H., Jiang, K., Zhao, G., Shaukat, A., Deng, G., & Qiu, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14276 · Cited by 157 · see citing works

Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC–MS/MS

Yuan, M., Kremer, D. M., Huang, H., Breitkopf, S. B., Ben‐Sahra, I., Manning, B. D., Lyssiotis, C. A., & Asara, J. M. (2019) · Nature Protocols · doi:10.1038/s41596-018-0102-x · Cited by 155 · see citing works

Selenium‐ and Tellurium‐Containing Multifunctional Redox Agents as Biochemical Redox Modulators with Selective Cytotoxicity

Jamier, V., Ba, L. A., & Jacob, C. (2010) · Chemistry - A European Journal · doi:10.1002/chem.201000884 · Cited by 148 · see citing works

Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance

Bekele, R., Venkatraman, G., Liu, R., Tang, X., Mi, S., Benesch, M. G. K., Mackey, J. R., Godbout, R., Curtis, J. M., McMullen, T. P. W., et al. (2016) · Scientific Reports · doi:10.1038/srep21164 · Cited by 146 · see citing works

Endocrine treatment in breast cancer: Cure, resistance and beyond

Tryfonidis, K., Zardavas, D., Katzenellenbogen, B. S., & Piccart, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.008 · Cited by 142 · see citing works

Estrogen signaling: An emanating therapeutic target for breast cancer treatment

Saha, T., Makar, S., Swetha, R., Gutti, G., & Singh, S. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.023 · Cited by 137 · see citing works

Synthesis and Selective Anticancer Activity of Organochalcogen Based Redox Catalysts

Doering, M., Ba, L. A., Lilienthal, N., Nicco, C., Scherer, C., Abbas, M., Zada, A. A. P., Coriat, R., Burkholz, T., Wessjohann, L. A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100576z · Cited by 136 · see citing works

Selenium-Containing Chrysin and Quercetin Derivatives: Attractive Scaffolds for Cancer Therapy

Martins, I. L., Charneira, C., Gandin, V., da Silva, J. F., Justino, G. C., Telo, J. P., Vieira, A. J. S. C., Marzano, C., & Antunes, A. M. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00230 · Cited by 120 · see citing works

Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer

Lu, Y., & Liu, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00913 · Cited by 119 · see citing works

Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer

Tang, C. C., Li, C., Zhang, S., Hu, Z., Wu, J., Dong, C., Huang, J., & Zhou, H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00099 · Cited by 113 · see citing works

AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer

Kubli, S. P., Bassi, C., Roux, C., Wakeham, A. C., Göbl, C., Zhou, W., Jafari, S. M., Snow, B. E., Jones, L., Palomero, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815126116 · Cited by 112 · see citing works

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

Emons, G., Mustea, A., & Tempfer, C. M. (2020) · Cancers · doi:10.3390/cancers12092535 · Cited by 105 · see citing works

Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology

Ikeda, K., Horie‐Inoue, K., & Inoue, S. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.123 · Cited by 102 · see citing works

Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy

Sanmartín, C., Plano, D., & Palop, J. A. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708785740625 · Cited by 101 · see citing works

Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation

Quirke, V. M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00620 · Cited by 92 · see citing works

Hexokinase 1 blocks apoptotic signals at the mitochondria

Schindler, A., & Foley, E. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.035 · Cited by 75 · see citing works

Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure

Zhou, H., Comninos, J. S., Stossi, F., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0506773 · Cited by 74 · see citing works

Synthesis and Biological Evaluation of Selenium-Containing 4-Anilinoquinazoline Derivatives as Novel Antimitotic Agents

An, B., Wang, B., Hu, J., Xu, S., Huang, L., Li, X., & Chan, A. S. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00128 · Cited by 74 · see citing works

Synthesis of Selenium-Quinone Hybrid Compounds with Potential Antitumor Activity via Rh-Catalyzed C-H Bond Activation and Click Reactions

Jardim, G. A. M., Lima, D. J. B., Valença, W. O., Lima, D. J. B., Cavalcanti, B. C., Pessoa, C., Rafique, J., Braga, A. L., Jacob, C., Júnior, E. N. D. S., et al. (2017) · Molecules · doi:10.3390/molecules23010083 · Cited by 71 · see citing works

The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk

Williams‐Brown, M. Y., Salih, S. M., Xu, X., Veenstra, T. D., SAEED, M. K., Theiler, S., Diaz‐Arrastia, C., & Salama, S. A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.05.001 · Cited by 59 · see citing works

Hexokinases inhibit death receptor–dependent apoptosis on the mitochondria

Lauterwasser, J., Todt, F., Oelgeklaus, A., Schreiner, A., Funk, K., Falquez-Medina, H., Klesse, R., Jahreis, G., Zerbes, R. M., O’Neill, K. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021175118 · Cited by 52 · see citing works

Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in resistant T-lymphoma

Ali, W., Spengler, G., Kincses, A., Nové, M., Battistelli, C., Latacz, G., Starek, M., Dąbrowska, M., Honkisz-Orzechowska, E., Romanelli, A., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112435 · Cited by 49 · see citing works

Activable Targeted Protein Degradation Platform Based on Light-triggered Singlet Oxygen

Zhang, S., Li, Y., Li, T., Zhang, Y., Li, H., Cheng, Z., Peng, N., Liu, Y., Xu, J., & He, H. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02037 · Cited by 48 · see citing works

Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer

Ning, W., Hu, Z., Tang, C. C., Yang, L., Zhang, S., Dong, C., Huang, J., & Zhou, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00224 · Cited by 47 · see citing works

Tamoxifen and oxidative stress: an overlooked connection

Ahmed, N. S., Samec, M., Líšková, A., Kubatka, P., & Saso, L. (2021) · Discover Oncology · doi:10.1007/s12672-021-00411-y · Cited by 45 · see citing works

Ascorbate kills breast cancer cells by rewiring metabolism via redox imbalance and energy crisis

Ghanem, A., Melzer, A. M., Zaal, E. A., Neises, L., Baltissen, D., Matar, O., Glennemeier-Marke, H., Almouhanna, F., Theobald, J., el Maaty, M. A. A., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.012 · Cited by 38 · see citing works

Celebrating Two Centuries of Research in Selenium Chemistry: State of the Art and New Prospective

Santi, C., & Bagnoli, L. (2017) · Molecules · doi:10.3390/molecules22122124 · Cited by 34 · see citing works

Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer

He, M., Ning, W., Hu, Z., Huang, J., Dong, C., & Zhou, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112281 · Cited by 33 · see citing works

Estrogen Receptors as Therapeutic Targets in Breast Cancer

Ariazi, E. A., Ariazi, J. L., Cordera, F., & Jordan, V. C. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776173474 · Cited by 32 · see citing works

Development of Selective Estrogen Receptor Modulator (SERM)‐Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7‐Oxabicyclo[2.2.1]hept‐5‐ene Scaffold Core Ligands

Zheng, Y., Zhu, M., Srinivasan, S., Nwachukwu, J. C., Cavett, V. J., Min, J., Carlson, K. E., Wang, P., Dong, C., Katzenellenbogen, J. A., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200048 · Cited by 31 · see citing works

Synthesis and study of the cancer cell growth inhibitory properties of α-, γ-tocopheryl and γ-tocotrienyl 2-phenylselenyl succinates

Vraka, P. S., Drouza, C., Rikkou, M., Odysseos, A. D., & Keramidas, A. D. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.11.045 · Cited by 30 · see citing works

A Multi-Omics Study Revealing the Metabolic Effects of Estrogen in Liver Cancer Cells HepG2

Shen, M., Xu, M., Zhong, F., Crist, M., Prior, A. B., Yang, K., Allaire, D. M., Choueiry, F., Zhu, J., & Shi, H. (2021) · Cells · doi:10.3390/cells10020455 · Cited by 23 · see citing works

Pyridoxine enhances chemo-responsiveness of breast cancer stem cells via redox reconditioning.

Banerjee, S., Mukherjee, S., Bhattacharya, A., Basak, U., Chakraborty, S., Paul, S., Khan, P., Jana, K., Hazra, T., & Das, T. (2020) · Free Radical Biology & Medicine · doi:10.1016/j.freeradbiomed.2020.02.031 · Cited by 16 · see citing works

Uterine glycolytic enzyme expression is affected by knockout of different estrogen receptor subtypes

Hu, M., Zhang, Y.-H., Egecioglu, E., Li, X., Shao, L. R., & Billig, H. (2019) · Biomedical Reports · doi:10.3892/br.2019.1234 · Cited by 9 · see citing works

Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer <i>In Vitro</i> and <i>In Vivo</i>

Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39 · see citing works

Robust ERα-Targeted Near-Infrared Fluorescence Probe for Selective Hydrazine Imaging in Breast Cancer

Tang, C. C., Tong, H., Liu, B., Wang, X., Jin, Y., Tian, E., & Wang, F. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03395 · Cited by 39 · see citing works

Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer

Xin, L., Wang, C., Cheng, Y., Wang, H., Guo, X., Deng, X., Deng, X., Xie, B., Hu, H., Min, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00196 · Cited by 38 · see citing works

SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer

Lu, Y., Sheng, X., Liu, C., Liang, Z., Wang, X., Liu, L., Wen, Z., Yang, Z., Du, Q., & Liu, W. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106731 · Cited by 37 · see citing works

Organoselenium compounds beyond antioxidants

Mamgain, R., Mishra, G., Kriti, S., & Singh, F. V. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2435254 · Cited by 35 · see citing works

Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability

Zhang, S., Qing, L., Wang, Z., Zhang, Y., Li, Y., Fang, H., Liu, Y., & He, H. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02006 · Cited by 33 · see citing works

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer

Wang, Y., Min, J., Deng, X., Feng, T., Hu, H., Guo, X., Cheng, Y., Xie, B., Yang, Y., Chen, C.-C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.005 · Cited by 28 · see citing works

Therapeutic significance of molecular hybrids for breast cancer research and treatment

Shagufta, & Ahmad, I. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00356b · Cited by 27 · see citing works

Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer

Deng, X., Deng, X., Ning, W., Xin, L., Li, Q., Hu, Z., Xie, B., Liang, K., Min, C., Dong, C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00465 · Cited by 26 · see citing works

Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha

Jiang, S., Liu, K., Jiang, T., Li, H., Wei, X., Wan, X., Zhong, C., Gong, R., Chen, Z., Zou, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62288-7 · Cited by 23 · see citing works

Selenium(II)‐Nitrogen Exchange (SeNEx) Chemistry: A Good Chemistry Suitable for Nanomole‐Scale Parallel Synthesis, DNA‐encoded Library Synthesis and Bioconjugation

Hou, W., Hou, S., Gu, Y., Zhang, S., Ma, P., Hu, H., & Xu, H. (2024) · ChemBioChem · doi:10.1002/cbic.202400641 · Cited by 18 · see citing works

Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer

Xin, L., Min, J., Hu, H., Li, Y., Du, C., Xie, B., Cheng, Y., Deng, X., Deng, X., Shen, K., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115328 · Cited by 16 · see citing works

Applications of Bridgehead Heterocycles in Drug Design and Medicinal Chemistry

Martino, S. D., Amico, P., & Rosa, M. D. (2025) · Topics in Current Chemistry · doi:10.1007/s41061-025-00502-2 · Cited by 16 · see citing works

Targeting hexokinase 2 for oral cancer therapy: structure-based design and validation of lead compounds

Chakraborty, P., Lubna, S., Bhuin, S., Deepika, K., Chakravarty, M., Trinath, J., & Yogeeswari, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1346270 · Cited by 14 · see citing works

Highly selective and AI-predictable Se–N exchange chemistry between benzoselenazolones and boronic acids for programmable, parallel, and DNA-encoded library synthesis

Zhou, W., Wang, Y., Zhang, S., Zhang, C., Pang, J., Hou, S., Li, J., Yao, Y., Su, A., Ma, P., et al. (2025) · Chemical Science · doi:10.1039/d5sc05512a · Cited by 13 · see citing works

Targeted Recruitment and Degradation of Estrogen Receptor α by Photothermal Polydopamine Nanoparticles for Breast Tumor Ablation

Zhang, Y., Ding, X., Xie, F., Gao, M., Qiu, J., Wang, Z., Qing, L., Yan, J., Peng, N., Li, Y., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200960 · Cited by 13 · see citing works

Design, Synthesis and Antitumor Activity of Novel Selenium-Containing Tepotinib Derivatives as Dual Inhibitors of c-Met and TrxR

Hu, J., Chen, L., Lu, Z., Yao, H., Hu, Y., Feng, L., Pang, Y., Wu, J., Yu, Z., & Chen, W. (2023) · Molecules · doi:10.3390/molecules28031304 · Cited by 12 · see citing works

Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability

Xu, J., Zhao, A., Chen, D., Wang, J., Ma, J., Qing, L., Li, Y., Fang, H., He, H., Pan, W., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116160 · Cited by 11 · see citing works

Rational Design of Methylene Blue–Raloxifene Conjugates for Efficient Breast Tumor Elimination Triggered by ERα Degradation

Zhang, Y., Yu, Q., Wang, Z., Qing, L., Mo, X., Liu, B., Chai, Y., Yu, B., Dong, Y., Pan, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00490 · Cited by 10 · see citing works

Selenium: The Emerging Element in the Medicinal Chemist’s Toolkit

Cui, L., Hou, W., & Xu, H. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2024-0041 · Cited by 9 · see citing works

Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists

Chen, X., Xu, S., Yang, S. C., Yu, Z.-Z., Chen, Y., Wu, H., Bao, Q., You, Q., Guo, X., & Jiang, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02616 · Cited by 10 · see citing works

Synthesis, antioxidant and antitumoral activity of new 5′-arylchalcogenyl-3′- N -( E )-feruloyl-3′, 5′-dideoxy-amino-thymidine (AFAT) derivatives

Leal, J. G., Piccoli, B. C., Oliveira, C. S., da Silva, F. D., Omage, F. B., da Rocha, J. B. T., Sonego, M. S., Segatto, N. V., Seixas, F. K., Collares, T. V., et al. (2022) · New Journal of Chemistry · doi:10.1039/d2nj03487e · Cited by 8 · see citing works

Copper(II)-Catalyzed Radical-Type Selenium(II)–Nitrogen Exchange Chemistry between Benzoselenazolones and Hydrazines

Pang, J., Qu, Y., Lv, J., Xu, H., Rao, G., & Hou, W. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c00487 · Cited by 5 · see citing works

Research progress of flavonoids targeting estrogen receptor in the treatment of breast cancer

Long, J., Ye, P., Yuan, W., Yang, Q., Wang, Z., Xiao, H. P., Xie, Z., Lei, X., Yang, X., Deng, X., et al. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118106 · Cited by 5 · see citing works

Advances in combination therapy for the treatment of estrogen receptor positive breast cancer

Liu, L., Zhao, Z., Zou, F., Lu, Y., & Lu, Y. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111451 · Cited by 4 · see citing works

Selective Estrogen Receptor Modulators (SERMs): Advances, Challenges, and Future Prospects in ER+ Breast Cancer Therapy

Saini, A., Kalita, R., Nath, T., Singh, A. K. P., Goswami, D., & Sethi, K. K. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70206 · Cited by 4 · see citing works

Development of trisubstituted thiophene-3-arboxamide selenide derivatives as novel EGFR kinase inhibitors with cytotoxic activity

Makhal, P. N., Sood, A., Shaikh, A. S., Dayare, L. N., Khatri, D. K., & Kaki, V. R. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00403a · Cited by 3 · see citing works

Exploring variations in glycolytic and gluconeogenic enzymes and isoforms across breast cancer cell lines and tissues

Luís, C., Fernandes, R., & Soares, R. A. (2024) · Carbohydrate Research · doi:10.1016/j.carres.2024.109169 · Cited by 2 · see citing works

Computer-aided design of a fluorescent MAT2A inhibitor for visualized cancer synthetic lethality

Wang, Z., Zhou, W., Chen, X., Wu, Y., Huang, Y., Li, F., Gong, Z., Xu, J., He, H., & Zhang, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107582 · Cited by 2 · see citing works

Discovery of novel coumarin-sulfonates as tubulin polymerization inhibitors targeting the colchicine-binding site with potent anticancer activities

Zhao, D., Wu, J., Song, J.-S., Chen, B., Du, Y., Wu, M., Niu, J.-B., Song, J., Xu, Y. C., & Zhang, S. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130284 · Cited by 2 · see citing works

A selenium-containing selective estrogen receptor modulator to overcome drug resistance of chronic myeloid leukemia

Liu, J., Yang, C., Gu, D., Guo, L., Zeng, Y., Guo, Q., Yang, Y., Meng, Q., Shu, J., Liu, W., et al. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02235-5

Drug-Conjugated Tam-NHC-Gold(I) Complexes Overcome ESR1 Mutant Breast Cancer Resistance and Downregulate the RAMP3/CALCR Signaling Pathway

Lu, Y., Liu, L., Liang, Z., Schroder, W. A., Wen, Z., Zheng, T., Niu, B., Xie, C., Zhang, H., Min, J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02812

Prenylated 4-Hydroxycoumarin derivatives as inducers of CDK4/6-mediated cell cycle arrest: From design and synthesis to in vitro and in vivo evaluation of their anti-breast Cancer activity

Pan, X., Wang, S., Lai, K., Dong, H., Zheng, K., Shen, Y., Yu, A., Lin, C., & Gan, C. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110344

BindingDB Entry 50019348: Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.

BindingDB (2024) · UC San Diego · doi:10.7270/q2zg6xk6

BindingDB Entry 50021214: Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.

BindingDB (2025) · UC San Diego · doi:10.7270/q2xd1691

BindingDB Entry 50023299: Research progress of flavonoids targeting estrogen receptor in the treatment of breast cancer.

BindingDB (2026) · UC San Diego · doi:10.7270/q21j9gpm

BindingDB Entry 50020674: Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability.

BindingDB (2024) · UC San Diego · doi:10.7270/q2377f57

BindingDB Entry 50020244: Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.

BindingDB (2024) · UC San Diego · doi:10.7270/q2b85dkz

BindingDB Entry 50020048: Development of trisubstituted thiophene-3-arboxamide selenide derivatives as novel EGFR kinase inhibitors with cytotoxic activity.

BindingDB (2024) · UC San Diego · doi:10.7270/q2p84h9b

BindingDB Entry 50021688: Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability.

BindingDB (2025) · UC San Diego · doi:10.7270/q2j96c2d

BindingDB Entry 50019705: Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer

BindingDB (2024) · UC San Diego · doi:10.7270/q2sf31jz

BindingDB Entry 50023590: Rational Design of Methylene Blue-Raloxifene Conjugates for Efficient Breast Tumor Elimination Triggered by ERα Degradation.

BindingDB (2026) · UC San Diego · doi:10.7270/q2183cgn

BindingDB Entry 50023074: Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists.

BindingDB (2026) · UC San Diego · doi:10.7270/q21n8600

Discovery of a multi-target compound for estrogen receptor-positive (ER+) breast cancer: Involvement of aromatase and ERs

Almeida, C. F., Teixeira, N. A. A., de Oliveira, A. L. N., Augusto, T. V., Correia‐da‐Silva, G., Ramos, M. J., Fernandes, P. A., & Amaral, C. (2020) · Biochimie · doi:10.1016/j.biochi.2020.11.023 · Cited by 25 · see citing works

Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure–activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides

Zhu, M., Zhang, C., Nwachukwu, J. C., Srinivasan, S., Cavett, V. J., Zheng, Y., Carlson, K. E., Dong, C., Katzenellenbogen, J. A., Nettles, K. W., et al. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob26531a · Cited by 38 · see citing works

Abstract 5574: Development of novel breast cancer therapeutics for anti-estrogen resistant breast cancer.

Ma, Y., Preet, A., Hu, C., Kumar, A., Ma, J., Tomita, Y. A., & Rosen, E. M. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5574

Development of Selective Estrogen Receptor Modulator (SERM)‐Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7‐Oxabicyclo[2.2.1]hept‐5‐ene Scaffold Core Ligands

Zheng, Y., Zhu, M., Srinivasan, S., Nwachukwu, J. C., Cavett, V. J., Min, J., Carlson, K. E., Wang, P., Dong, C., Katzenellenbogen, J. A., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200048 · Cited by 31 · see citing works

An Innovative Non-Hormonal Strategy Targeting Redox Active Metals to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast CancerPreprint

Shehadeh-Tout, F., Milioli, H. H., Roslan, S., Jansson, P. J., Dharmasivam, M., Graham, D., Anderson, R. L., Wijesinghe, T. P., Azad, M. G., Richardson, D. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.02.526543 · Cited by 2 · see citing works